16
Oct
2012
Posted in I - Series A, Q - 1Q12, R - MID WEST, X - Device (Diagnostic), X - Device (Sequencing), XX - IN
Strand Diagnostics (Indianapolis, IN) a commercial-stage molecular diagnostics company focused on DNA screening of breast and prostate biopsy samples and patient DNA for molecular cancer diagnosis verification, closed a $30M Series A financing. Participants include NantWorks.
Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.